Kewaunee Scientific Corporation

As of July 31, 2026, Kewaunee Scientific Corporation carries a market capitalization of 103.41M, placing it among publicly traded companies globally. Its enterprise value stands at 126.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Kewaunee Scientific Corporation's next confirmed earnings release is scheduled for December 16, 2026.

As of July 31, 2026, Kewaunee Scientific Corporation has 2.90M shares outstanding.

As of July 31, 2026, Kewaunee Scientific Corporation trades at a trailing price-to-earnings ratio of 12.45. The price-to-sales ratio is 0.37, and the price-to-book ratio stands at 1.38.

As of July 31, 2026, Kewaunee Scientific Corporation trades at an EV/EBITDA multiple of 5.91 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.46 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 8.39 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Kewaunee Scientific Corporation trades at an EV/FCF ratio of 7.29, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 126.43M versus a market cap of 103.41M, with the gap driven by net debt and cash on the balance sheet.

As of July 31, 2026, Kewaunee Scientific Corporation maintains a current ratio of 2.20, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 37.62, indicating elevated leverage, while an interest coverage ratio of 6.23 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended July 31, 2026, Kewaunee Scientific Corporation posted a return on equity (ROE) of 11.59, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.02 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.46, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.81, useful for judging operating efficiency across full business cycles. The company generates approximately 224,465.59 in revenue per employee across its workforce of 1,235.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.12 indicates how many times Kewaunee Scientific Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended July 31, 2026, Kewaunee Scientific Corporation recorded 3.22M in income tax expense. That works out to an effective tax rate of 26.06, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 12.37M, leaving 8.23M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on November 4, 2026, Kewaunee Scientific Corporation's stock has declined approximately 16.94% over the past 52 weeks. The 50-day moving average sits at 34.40, while the 200-day moving average is 36.79.

Over the twelve months ended July 31, 2026, Kewaunee Scientific Corporation generated 277.22M in revenue and converted that into 8.23M in net income, yielding earnings per share of 3.08. EBITDA reached 21.39M, while operating income came in at 15.06M.

As of July 31, 2026, Kewaunee Scientific Corporation holds 8.25M in cash and equivalents against 29.05M in total debt, resulting in a net debt position of 10.86M. Total book value stands at 75.01M, with working capital of 56.72M providing operational flexibility.

Kewaunee Scientific Corporation produced 14.82M in operating cash flow over the twelve months ended July 31, 2026.

Over the twelve months ended July 31, 2026, Kewaunee Scientific Corporation posted a gross margin of 28.55, reflecting its pricing power and cost economics. The operating margin of 5.43 and net profit margin of 2.97 provide insight into operational efficiency.

These figures cover the twelve months ended July 31, 2026. Free cash flow yield stands at 13.96, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 19.69, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Kewaunee Scientific Corporation shareholders.

Kewaunee Scientific Corporation's most recent stock split took place on January 7, 1985 with a 2:3 split ratio.

As of July 31, 2026, Kewaunee Scientific Corporation has an Altman Z-Score of 3.98, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.